Review ArticleReview Article
Open Access

Acinetobacter baumannii

A multidrug-resistant pathogen, has emerged in Saudi Arabia

Jehad A. Aldali
Saudi Medical Journal August 2023, 44 (8) 732-744; DOI: https://doi.org/10.15537/smj.2023.44.8.20230194

References

  1. 1.↵
    1. Dolma KG.
    Acinetobacter baumannii: An overview of emerging multidrug-resistant pathogen. Med J Malaysia 2022; 77: 357.
    OpenUrl
  2. 2.↵
    1. Vijayakumar S,
    2. Biswas I,
    3. Veeraraghavan B.
    Accurate identification of clinically important Acinetobacter spp.: an update. Future Sci OA 2019; 5: FSO395.
    OpenUrl
  3. 3.↵
    1. Vaneechoutte M,
    2. Dijkshoorn L,
    3. Tjernberg I,
    4. Elaichouni A,
    5. de Vos P,
    6. Claeys G, et al.
    Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J Clin Microbiol 1995; 33: 11–15.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Han K-S,
    2. Kim Y,
    3. Choi S,
    4. Oh S,
    5. Park S,
    6. Kim S-H, et al.
    Rapid identification of Lactobacillus acidophilus by restriction analysis of the 16S–23S rRNA intergenic spacer region and flanking 23S rRNA gene. Biotechnology letters 2005; 27: 1183–1188.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. La Scola B,
    2. Gundi VA,
    3. Khamis A,
    4. Raoult D.
    Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol 2006; 44: 827–832.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Owen L,
    2. Laird K.
    The role of textiles as fomites in the healthcare environment: A review of the infection control risk. PeerJ 2020; 8: e9790.
    OpenUrlCrossRef
  7. 7.↵
    1. Peacock SJ,
    2. Parkhill J,
    3. Brown NM.
    Changing the paradigm for hospital outbreak detection by leading with genomic surveillance of nosocomial pathogens. Microbiology (Reading) 2018; 164: 1213.
    OpenUrlCrossRef
  8. 8.↵
    1. Cillóniz C,
    2. Dominedò C,
    3. Torres A.
    Multidrug resistant gram-negative bacteria in community-acquired pneumonia. Annual Update in Intensive Care and Emergency Medicine 2019 2019:459–475.
    OpenUrl
  9. 9.↵
    1. Joly-Guillou M-L,
    2. Brun-Buisson C.
    Epidemiology of Acinetobacter spp.: surveillance and management of outbreaks. In: Acinetobacter: CRC Press; 2020. pp. 71–100.
  10. 10.↵
    1. Meschiari M,
    2. Kaleci S,
    3. Orlando G,
    4. Selmi S,
    5. Santoro A,
    6. Bacca E, et al.
    Risk factors for nosocomial rectal colonization with carbapenem-resistant Acinetobacter baumannii in hospital: a matched case–control study. Antimicrob Resist Infect Control 2021; 10:1–11.
    OpenUrl
  11. 11.↵
    1. Gales AC,
    2. Seifert H,
    3. Gur D,
    4. Castanheira M,
    5. Jones RN,
    6. Sader HS.
    Antimicrobial susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY antimicrobial surveillance program (1997–2016). Open Forum Infect Dis 2019; 6: S34–S46.
    OpenUrlCrossRef
  12. 12.↵
    1. Cassini A,
    2. Högberg LD,
    3. Plachouras D,
    4. Quattrocchi A,
    5. Hoxha A,
    6. Simonsen GS, et al.
    Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 2019; 19: 56–66.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Ibrahim ME.
    Prevalence of Acinetobacter baumannii in Saudi Arabia: risk factors, antimicrobial resistance patterns and mechanisms of carbapenem resistance. Ann Clin Microbiol Antimicrob 2019; 18 :1–12.
    OpenUrlCrossRef
  14. 14.↵
    1. Mah MW,
    2. Memish ZA,
    3. Cunningham G,
    4. Bannatyne RM.
    Outbreak of Acinetobacter baumannii in an intensive care unit associated with tracheostomy. Am J Infect Control 2001; 29: 284–288.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Senok A,
    2. Garaween G,
    3. Raji A,
    4. Khubnani H,
    5. Sing GK,
    6. Shibl A.
    Genetic relatedness of clinical and environmental Acinetobacter baumanii isolates from an intensive care unit outbreak. J Infect Dev Ctries 2015; 9: 665–669.
    OpenUrl
  16. 16.↵
    1. El-Ageery S.
    Epidemiological investigation of nosocomial infection with multidrug-resistant Acinetobacter baumannii. Eur Rev Med Pharmacol Sci 2022; 16: 1834–1839.
    OpenUrl
  17. 17.↵
    1. Asaad AM,
    2. Al-Ayed MSZ,
    3. Qureshi MA.
    Emergence of unusual nonfermenting gram-negative nosocomial pathogens in a Saudi hospital. Jpn J Infect Dis 2013; 66: 507–511.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Luo G,
    2. Spellberg B,
    3. Gebremariam T,
    4. Bolaris M,
    5. Lee H,
    6. Fu Y, et al.
    Diabetic murine models for Acinetobacter baumannii infection.J Antimicrob Chemother 2012; 67: 1439–1445.
  19. 19.↵
    1. Gowda KL,
    2. Marie MA,
    3. Al-Sheikh YA,
    4. John J,
    5. Gopalkrishnan S,
    6. Shashidhar PC, et al.
    A 6-year surveillance of antimicrobial resistance patterns of Acinetobacter baumannii bacteremia isolates from a tertiary care hospital in Saudi Arabia during 2005–2010. Libyan J Med 2014; 9: 24039.
    OpenUrl
  20. 20.↵
    1. Smitten KL,
    2. Thick EJ,
    3. Southam HM,
    4. de la Serna JB,
    5. Foster SJ,
    6. Thomas JA.
    Mononuclear ruthenium (II) theranostic complexes that function as broad-spectrum antimicrobials in therapeutically resistant pathogens through interaction with DNA. Chemical Science 2020; 11: 8828–8838.
    OpenUrl
  21. 21.↵
    1. Kwon J,
    2. Mistry T,
    3. Ren J,
    4. Johnson ME,
    5. Mehboob S.
    A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii. Bioorg Med Chem 2018; 26: 65–76.
    OpenUrlCrossRef
  22. 22.↵
    1. Liu Y,
    2. Li R,
    3. Xiao X,
    4. Wang Z.
    Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria. Crit Rev Microbiol 2019; 45: 301–314.
    OpenUrl
  23. 23.↵
    1. Zhang Y,
    2. Fan B,
    3. Luo Y,
    4. Tao Z,
    5. Nie Y,
    6. Wang Y, et al.
    Comparative analysis of carbapenemases, RND family efflux pumps and biofilm formation potential among Acinetobacter baumannii strains with different carbapenem susceptibility. BMC Infec Dis 2021; 21: 1–7.
    OpenUrl
  24. 24.↵
    1. Kyriakidis I,
    2. Vasileiou E,
    3. Pana ZD,
    4. Tragiannidis A.
    Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens 2021; 10: 373.
    OpenUrl
  25. 25.↵
    1. Wu H-J,
    2. Xiao Z-G,
    3. Lv X-J,
    4. Huang H-T,
    5. Liao C,
    6. Hui C-Y, et al.
    Drug–resistant Acinetobacterábaumannii: From molecular mechanisms to potential therapeutics. Exp Ther Med 2023; 25: 1–10.
    OpenUrl
  26. 26.↵
    1. Tooke CL,
    2. Hinchliffe P,
    3. Bragginton EC,
    4. Colenso CK,
    5. Hirvonen VH,
    6. Takebayashi Y, et al.
    β-Lactamases and β-Lactamase Inhibitors in the 21st Century. Journal of molecular biology 2019; 431: 3472–3500.
    OpenUrlCrossRef
  27. 27.↵
    1. Nikibakhsh M,
    2. Firoozeh F,
    3. Badmasti F,
    4. Kabir K,
    5. Zibaei M.
    Molecular study of metallo-β-lactamases and integrons in Acinetobacter baumannii isolates from burn patients. BMC Infect Dis 2021; 21: 782.
    OpenUrl
  28. 28.↵
    1. Tsivkovski R,
    2. Totrov M,
    3. Lomovskaya O.
    Biochemical characterization of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases. Antimicrob Agents Chemother 2020; 64: e00130–00120.
    OpenUrl
  29. 29.↵
    1. Weinberg S,
    2. Villedieu A,
    3. Bagdasarian N,
    4. Karah N,
    5. Teare L,
    6. Elamin W.
    Control and management of multidrug resistant Acinetobacter baumannii: A review of the evidence and proposal of novel approaches. IPP 2020; 2: 100077.
  30. 30.↵
    1. Mancuso G,
    2. Midiri A,
    3. Gerace E,
    4. Biondo C.
    Bacterial antibiotic resistance: The most critical pathogens. Pathogens 2021; 10: 1310.
    OpenUrl
  31. 31.↵
    1. Pompilio A,
    2. Scribano D,
    3. Sarshar M,
    4. Di Bonaventura G,
    5. Palamara AT,
    6. Ambrosi C.
    Gram-negative bacteria holding together in a biofilm: the Acinetobacter baumannii way. Microorganisms 2021; 9: 1353.
    OpenUrl
  32. 32.↵
    1. Nasr P. Genetics
    , epidemiology, and clinical manifestations of multidrug-resistant Acinetobacter baumannii. Journal of Hospital Infection 2020; 104: 4–11.
    OpenUrlCrossRef
  33. 33.↵
    1. Kempf M,
    2. Rolain J-M.
    Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. International journal of antimicrobial agents 2012; 39(2):105–114.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Cerini P,
    2. Meduri FR,
    3. Tomassetti F,
    4. Polidori I,
    5. Brugneti M,
    6. Nicolai E, et al.
    Trends in antibiotic resistance of nosocomial and community-acquired infections in Italy. Antibiotics 2023; 12: 651.
    OpenUrl
  35. 35.↵
    1. Tacconelli E,
    2. Carrara E,
    3. Savoldi A,
    4. Harbarth S,
    5. Mendelson M,
    6. Monnet DL, et al.
    Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18: 318–327.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Tamma PD,
    2. Aitken SL,
    3. Bonomo RA,
    4. Mathers AJ,
    5. van Duin D,
    6. Clancy CJ.
    Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin Infect Dis 2022; 74: 2089–2114.
    OpenUrl
  37. 37.↵
    1. Falcone M,
    2. Tiseo G,
    3. Nicastro M,
    4. Leonildi A,
    5. Vecchione A,
    6. Casella C, et al.
    Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients. Clin Infect Dis 2021; 72: 2021–2024.
    OpenUrl
  38. 38.↵
    1. Zaidan N,
    2. Hornak JP,
    3. Reynoso D.
    Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination. Antimicrob Agents Chemother 2021; 65: e00924–00921.
    OpenUrl
  39. 39.↵
    1. Al Johani SM,
    2. Akhter J,
    3. Balkhy H,
    4. El-Saed A,
    5. Younan M,
    6. Memish Z.
    Prevalence of antimicrobial resistance among gram-negative isolates in an adult intensive care unit at a tertiary care center in Saudi Arabia. Ann Saudi Med 2010; 30: 364–369.
    OpenUrlPubMedWeb of Science
  40. 40.↵
    1. Aly M,
    2. Tayeb H,
    3. Al Johani S,
    4. Alyamani E,
    5. Aldughaishem F,
    6. Alabdulkarim I, et al.
    Genetic diversity of OXA-51-like genes among multidrug-resistant Acinetobacter baumannii in Riyadh, Saudi Arabia. Eur J Clin Microbiol Infect Dis 2014; 33: 1223–1228.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Saeed NK,
    2. Kambal AM,
    3. El-Khizzi NA.
    Antimicrobial-resistant bacteria in a general intensive care unit in Saudi Arabia. Saudi Med J 2010; 31: 1341–1349.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Al-Agamy MH,
    2. Jeannot K,
    3. El-Mahdy TS,
    4. Shibl AM,
    5. Kattan W,
    6. Plésiat P, et al.
    First detection of GES-5 carbapenemase-producing Acinetobacter baumannii isolate. Microbial Drug Resistance 2017; 23: 556–562.
    OpenUrl
  43. 43.↵
    1. Kengkla K,
    2. Kongpakwattana K,
    3. Saokaew S,
    4. Apisarnthanarak A,
    5. Chaiyakunapruk N.
    Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother 2018; 73: 22–32.
    OpenUrlCrossRef
  44. 44.↵
    1. Al-Sultan AA.
    Diabetic patients are threatened by “superbugs” Acinetobacter baumannii In Saudi Arabia hospitals. Int J Infect Dis 2014; 21:351.
    OpenUrl
  45. 45.↵
    1. Kharaba A,
    2. Algethamy H,
    3. Hussein M,
    4. Al-Hameed FM,
    5. Alghamdi A,
    6. Hamdan A, et al.
    Incidence, outcomes, and predictors of Acinetobacter infection in Saudi Arabian critical care units. J Crit Care 2021; 66:109–116.
    OpenUrl
  46. 46.↵
    1. Al-Obeid S,
    2. Jabri L,
    3. Al-Agamy M,
    4. Al-Omari A,
    5. Shibl A.
    Epidemiology of extensive drug resistant Acinetobacter baumannii (XDRAB) at Security Forces Hospital (SFH) in Kingdom of Saudi Arabia (KSA). J Chemother 2015; 27: 156–162.
    OpenUrl
  47. 47.↵
    1. Aly M,
    2. Abu Alsoud N,
    3. Elrobh M,
    4. Al Johani S,
    5. Balkhy H.
    High prevalence of the PER-1 gene among carbapenem-resistant Acinetobacter baumannii in Riyadh, Saudi Arabia. Eur J Clin Microbiol Infect Dis 2016; 35:1759–1766.
    OpenUrl
  48. 48.↵
    1. Said KB,
    2. Al-Jarbou AN,
    3. Alrouji M,
    4. Al-Harbi HO.
    Surveillance of antimicrobial resistance among clinical isolates recovered from a tertiary care hospital in Al Qassim, Saudi Arabia. Int J Health Sci (Qassim) 2014; 8: 3.
    OpenUrl
  49. 49.↵
    1. Al Mobarak MF,
    2. Matbuli RM,
    3. Meir H,
    4. Al Gehani N,
    5. El Toukhy AAM,
    6. Al Qureshey KF, et al.
    Antimicrobial Resistance Patterns among Acinetobacter Baumannii Isolated from King Abdulaziz Hospital, Jeddah, Saudi Arabia: Four-Year Surveillance Study (2010-2013). Egypt J Med Microbiol 2014; 38: 1–8.
    OpenUrl
  50. 50.↵
    1. Alhaggass NSA,
    2. Amal A. Al-Hazzani
    . Antimicrobial Susceptibility and Molecular Characterization of Clinical Strains of Acinetobacter sp in the Qassim Area, Saudi Arabia. Sch Acad J Biosci 2022; 4:85–92.
    OpenUrl
  51. 51.↵
    1. Aljindan R,
    2. Bukharie H,
    3. Alomar A,
    4. Abdalhamid B.
    Prevalence of digestive tract colonization of carbapenem-resistant Acinetobacter baumannii in hospitals in Saudi Arabia. J Med Microbiol 2015; 64: 400–406.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Abdalhamid B,
    2. Hassan H,
    3. Itbaileh A,
    4. Shorman M.
    Characterization of carbapenem-resistant Acinetobacter baumannii clinical isolates in a tertiary care hospital in Saudi Arabia. New Microbiol 2014; 37: 65–73.
    OpenUrlPubMed
  53. 53.↵
    1. Aljindan R,
    2. Elhadi N.
    Genetic relationship of multi-resistant acinetobacter baumannii isolates in kingdom of Saudi Arabia. J Pure Appl Microbiol 2018; 12: 1951–1958.
    OpenUrl
  54. 54.↵
    1. Al-Sultan AA,
    2. Evans BA,
    3. Aboulmagd E,
    4. Al-Qahtani AA,
    5. Bohol MFF,
    6. Al-Ahdal MN, et al.
    Dissemination of multiple carbapenem-resistant clones of Acinetobacter baumannii in the Eastern District of Saudi Arabia. Front Microbiol 2015; 6: 634.
    OpenUrl
  55. 55.↵
    1. Al-Hamad A,
    2. Pal T,
    3. Leskafi H,
    4. Abbas H,
    5. Hejles H,
    6. Alsubikhy F, et al.
    Molecular characterization of clinical and environmental carbapenem resistant Acinetobacter baumannii isolates in a hospital of the Eastern Region of Saudi Arabia. J Infect Public Health 2020; 13: 632–636.
    OpenUrl
  56. 56.↵
    1. Al-Tawfiq JA,
    2. Mohandhas TX.
    Prevalence of antimicrobial resistance in Acinetobacter calcoaceticus-baumannii complex in a Saudi Arabian hospital.J Infect Public Health 2007; 28: 870–872.
  57. 57.↵
    1. Yasir M,
    2. Subahi AM,
    3. Shukri HA,
    4. Bibi F,
    5. Sohrab SS,
    6. Alawi M, et al.
    Bacterial community and genomic analysis of Carbapenem-resistant Acinetobacter baumannii Isolates from the environment of a health care facility in the western region of Saudi Arabia. Pharmaceuticals 2022; 15: 611.
    OpenUrl
  58. 58.↵
    1. Samah G,
    2. Hatem M,
    3. Nikhat M.
    Antimicrobial resistance pattern of Acinetobacter spp. isolated from clinical samples in a tertiary care hospital at Madinah, Saudi Arabia. Afr J Microbiol. Res 2018; 12: 723–729.
    OpenUrl
  59. 59.↵
    1. Haseeb A,
    2. Faidah HS,
    3. Bakhsh AR,
    4. Al Malki WH,
    5. Elrggal ME,
    6. Saleem F, et al.
    Antimicrobial resistance among pilgrims: a retrospective study from two hospitals in Makkah, Saudi Arabia. Int J Infect Dis 2016; 47: 92–94.
    OpenUrl
  60. 60.↵
    1. Alyamani EJ,
    2. Khiyami MA,
    3. Booq RY,
    4. Alnafjan BM,
    5. Altammami MA,
    6. Bahwerth FS.
    Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of Acinetobacter baumannii in Saudi Arabia. Ann Clin Microbiol Antimicrob 2015; 14: 1–9.
    OpenUrlCrossRef
  61. 61.↵
    1. Asghar AH,
    2. Faidah HS.
    Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from 2 hospitals in Makkah, Saudi Arabia. Saudi Med J 2009; 30(8):1017–1023.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Al-Sultan AA.
    Prevalence of High-Risk Antibiotic Resistant in the Holy Cities of Makkah and Al-Madinah. Open Microbiol J 2021; 15.
  63. 63.↵
    1. Khan MA,
    2. Mahomed MF,
    3. Ashshi AM,
    4. Faiz A.
    Drug resistance patterns of Acinetobacter baumannii in Makkah, Saudi Arabia. Pak J Med Res 2012; 51: 127–131.
    OpenUrl
  64. 64.↵
    1. Al-Gethamy MM,
    2. Faidah HS,
    3. Adetunji HA,
    4. Haseeb A,
    5. Ashgar SS,
    6. Mohanned TK, et al.
    Risk factors associated with multi-drug-resistant Acinetobacter baumannii nosocomial infections at a tertiary care hospital in Makkah, Saudi Arabia-a matched case–control study. J Int Med Res 2017; 45: 1181–1189.
    OpenUrl
  65. 65.↵
    1. Faidah HS,
    2. Momenah AM,
    3. El-Said HM,
    4. Barhameen AA,
    5. Ashgar SS,
    6. Johargy A, et al.
    Trends in the annual incidence of carbapenem resistant among gram negative bacilli in a large teaching hospital in Makah City, Saudi Arabia. J Tuberc Res 2017; 5: 229.
    OpenUrl
  66. 66.↵
    1. Selim SA,
    2. Hagag NI.
    Analysis of plasmids and restriction fragment length polymorphisms of Acinetobacter baumannii isolated from Hospitals-AL Jouf Region-KSA. Int J Med Health Sci 2013; 7: 225–231.
    OpenUrl
  67. 67.↵
    1. Bandy A,
    2. Almaeen AH.
    Pathogenic spectrum of blood stream infections and resistance pattern in Gram-negative bacteria from Aljouf region of Saudi Arabia. PLOS one 2020; 15: e0233704.
    OpenUrl
  68. 68.↵
    1. Taher I,
    2. Almaeen A,
    3. Aljourfi H,
    4. Bohassan E,
    5. Helmy A,
    6. El-Masry E, et al.
    Surveillance of antibiotic resistance among uropathogens in Aljouf region northern Saudi Arabia. Iran J Microbiol 2019; 11: 468.
    OpenUrl
  69. 69.↵
    1. Selim S,
    2. Faried OA,
    3. Almuhayawi MS,
    4. Mohammed OA,
    5. Saleh FM,
    6. Warrad M.
    Dynamic gene clusters mediating carbapenem-resistant Acinetobacter baumannii clinical isolates. Antibiotics 2022; 11: 168.
    OpenUrl
  70. 70.↵
    1. Almaghrabi MK,
    2. Joseph MR,
    3. Assiry MM,
    4. Hamid ME.
    Multidrug-resistant Acinetobacter baumannii: An emerging health threat in aseer region, Kingdom of Saudi Arabia.2018; 2018: 9182747.
    OpenUrl
  71. 71.↵
    1. Falagas ME,
    2. Vardakas KZ,
    3. Roussos NS.
    Trimethoprim/sulfamethoxazole for Acinetobacter spp.: a review of current microbiological and clinical evidence. Int J Antimicrob Agents 2015; 46: 231–241.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Elabd FM,
    2. Al-Ayed MS,
    3. Asaad AM,
    4. Alsareii SA,
    5. Qureshi MA,
    6. Musa HA-A.
    Molecular characterization of oxacillinases among carbapenem-resistant Acinetobacter baumannii nosocomial isolates in a Saudi hospital. J Infect Public Health 2015; 8: 242–247.
    OpenUrl
  73. 73.↵
    1. Alasmary MY.
    Antimicrobial Resistance Patterns and ESBL of Uropathogens Isolated from Adult Females in Najran Region of Saudi Arabia. Clinics and Practice 2021; 11: 650–658.
    OpenUrl
  74. 74.↵
    1. Aedh A.
    Prevalence of Acinetobacter infections among Intensive Care Unit’s patients in Najran. Int J Curr Res Med Sci 2017; 3: 122–128.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords